Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackstone Inc (BX) vs Medpace Holdings Inc (MEDP) Price & Performance

Blackstone IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Blackstone Inc vs Medpace Holdings Inc — how do they compare? Blackstone Inc trades at $126.38 (market cap $152.15B), while Medpace Holdings Inc trades at $536.29 (market cap $15.31B). The key difference: Blackstone Inc is far larger — about 9.9× Medpace Holdings Inc's market cap, and Blackstone Inc pays a 3.99% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

BXMEDP
Market Cap
$152.15B$15.31B
Sector
FinancialsTechnology
52-Week High
$188.68$620.59
52-Week Low
$102.12$308.88
Dividend Yield
3.99%
Enterprise Value
$14.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackstone Inc

Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.

Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.

Medpace Holdings Inc

MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.

Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackstone Inc

Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.

Read more on BX

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP